In this week’s episode of “The Readout LOUD,” STAT’s biotech podcast, hosts Adam, Allison, and Elaine delve into various topics, including the surprising earnings reports from Eli Lilly and Pfizer. They also discuss the potential impact of a Trump or Harris presidency on health care policy and the biopharma industry, as well as the opinions of investors and biopharma executives on the matter.
Eli Lilly’s Mounjaro and Zepbound sales falling short of expectations raised questions about the company’s performance. On the other hand, Pfizer exceeded expectations and addressed pressures from activist investors. The hosts also touch on Adam’s column regarding Trump, RFK Jr., and biotech stocks, exploring the possible implications of a second Trump administration on health care.
For more details on Eli Lilly’s earnings miss, readers can refer to a specific link provided. Similarly, information on Pfizer’s earnings and response to activist investors can be found in another link. The hosts invite listeners to explore Adam’s insights on the intersection of politics and biotech, including the potential effects of different presidential administrations on the health care landscape.
To further understand the implications of a Trump or Harris presidency on health care, additional resources are available for readers to explore. The hosts encourage listeners to tune in to “The Readout LOUD” on various podcast platforms to stay informed about the latest developments in the biotech industry.
Allison DeAngelis, the East Coast biotech and venture capital reporter at STAT, brings a unique perspective to the podcast by highlighting the convergence of scientific innovation and financial investments in the biotech sector. As a co-host of the podcast, her insights provide valuable context for listeners interested in the business side of biopharma.
Adam Feuerstein, a senior writer and biotech columnist, offers in-depth analysis on drug development, business trends, and the financial aspects of biotechnology. Through his contributions to the podcast and newsletter, Adam’s expertise helps listeners navigate the complex world of biopharma with clarity and insight.
Elaine Chen, the national biotech reporter at STAT, contributes her expertise to The Readout newsletter and podcast, offering comprehensive coverage of biotech news and developments. As a co-host of the podcast, Elaine’s insights provide a well-rounded perspective on the latest trends shaping the biotech landscape.
Overall, “The Readout LOUD” provides a platform for listeners to stay informed about the latest trends, earnings reports, and political developments influencing the biopharma industry. By exploring a range of topics and inviting expert guests, the podcast offers a comprehensive overview of the dynamic and ever-evolving world of biotechnology.
